Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $20.00 at Morgan Stanley

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective hoisted by Morgan Stanley from $15.00 to $20.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target would indicate a potential upside of 19.40% from the stock’s previous close.

Several other analysts also recently commented on the company. Oppenheimer raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $30.00 to $37.00 in a research note on Tuesday. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price objective for the company in a research note on Friday, June 6th. Jefferies Financial Group decreased their price target on Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday, July 24th. BMO Capital Markets reaffirmed a “market perform” rating and set a $50.00 price target (down from $70.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Finally, Mizuho reaffirmed a “neutral” rating and set a $14.00 price target (down from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Six analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $49.12.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $16.75 on Tuesday. The company has a market cap of $1.65 billion, a PE ratio of -6.23 and a beta of 0.45. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $145.00. The business has a 50 day moving average price of $24.69 and a 200-day moving average price of $62.20. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in SRPT. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth $31,000. Logan Capital Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $61,000. Ancora Advisors LLC raised its position in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after buying an additional 300 shares in the last quarter. Finally, Hurley Capital LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $76,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.